Intraperitoneal 5FU

Phase 2Small molecule

WWashington University School of Medicine

Intraperitoneal 5FU is one of 91 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaActive, not recruiting

Pseudomyxoma PeritoneiActive, not recruiting

Colorectal CancerActive, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Pseudomyxoma PeritoneiPhase 2

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Intraperitoneal 5FU

WWashington University School of Medicine

Phase 2

1 2

Emend IV

PORTRAZZA

Ketalar

AAultman Health Foundation

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Andriol

AAuxilium

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Colorectal Cancer

NCT01061515

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT01061515·21 enrolled

Colorectal Carcinoma1 trial

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

Completed·UUniversity Hospital, Ghent·Phase 2·NCT02399410·60 enrolled

Pseudomyxoma Peritonei1 trial

A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis

Terminated·WWashington University School of Medicine·Phase 2·NCT00352755·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Intraperitoneal 5FU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraperitoneal 5FU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraperitoneal 5FU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWashington University School of Medicine

Intraperitoneal 5FU

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Colorectal Cancer1 trial

Colorectal Carcinoma1 trial

Pseudomyxoma Peritonei1 trial

References

Drug Info

Quick Facts

Related News